Copyright: ©Author(s) 2026.
World J Gastroenterol. Apr 21, 2026; 32(15): 116679
Published online Apr 21, 2026. doi: 10.3748/wjg.v32.i15.116679
Published online Apr 21, 2026. doi: 10.3748/wjg.v32.i15.116679
Table 3 Predictive performances for different model in the validation set
| Metrics | Clinical | HE | Masson | HE + Masson | Multimodal model |
| AUC (mean) | 0.658 | 0.657 | 0.727 | 0.732 | 0.741 |
| AUC (95%CI) | 0.502-0.812 | 0.494-0.800 | 0.575-0.857 | 0.580-0.862 | 0.588-0.869 |
| Sensitivity | 0.586 | 0.828 | 0.724 | 0.724 | 0.655 |
| Specificity | 0.667 | 0.381 | 0.381 | 0.619 | 0.667 |
| PPV | 0.708 | 0.649 | 0.618 | 0.724 | 0.731 |
| NPV | 0.538 | 0.615 | 0.500 | 0.619 | 0.583 |
- Citation: Han W, Cheng DY, He QW, Wang SH, Gong SJ, Chen Y, Yang YP. Deep learning-based multimodal model for predicting on-treatment histological outcomes in chronic hepatitis B-associated advanced liver fibrosis. World J Gastroenterol 2026; 32(15): 116679
- URL: https://www.wjgnet.com/1007-9327/full/v32/i15/116679.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i15.116679